Democratic Governors Meet In New York City To Discuss Cannabis And Vaping

NEW YORK (AP) — The governors from several Northeastern states said Thursday they want to work together to regulate marijuana and vaping, including possible regional restrictions on flavored vaping products.

Democratic governors from New York, Connecticut, New Jersey and Pennsylvania met in New York City with health and legislative officials. Representatives from Massachusetts and Colorado were also on hand for the meeting.

“What we want to do is coordinate this on a regional basis,” said Connecticut Gov. Ned Lamont, noting how the “patchwork quilt of marijuana regulations makes no sense at all.” He said the group came up with “very preliminary” principles concerning how to regulate legalized, recreational marijuana, such as agreeing to have similar policies for THC content, edibles, advertising and taxation in order to dissuade people from turning to the illicit market.

Lamont said “different states are going to have different timeframes” to pass marijuana legislation and he didn’t foresee everyone enacting the exact same law at the same time. He said more work needs to be done and staff from the participating states will continue working together on the issue. Several of the governors unsuccessfully pushed for their states to allow recreational pot sales in the last year.

“We just want to make sure we go in with our eyes open and we’re consistent,” Lamont said.

On vaping, Lamont said there appeared to be “the most unity” among the officials on possibly outlawing flavored e-cigarettes next year, given their appeal to young people and the growing number of vaping-related lung illnesses and deaths across the country.

“I think you’ll see some unanimity on that at the start,” he said.


Earlier this month, a state appeals court temporarily blocked New York from enforcing Gov. Andrew Cuomo’s 90-day emergency ban on such products after the vaping industry sued to block the regulations. In Massachusetts, Republican Gov. Charlie Baker last month announced a statewide ban on the sale of vaping products, a measure that has been challenged in court.

Meanwhile, a new law just took effect in Connecticut that increased the age to 21 for someone to purchase vaping products.

Cuomo said a lack of federal action on pot and vaping regulations means it’s up to states to act. He noted that marijuana is often vaped and states should also consider that when considering marijuana legalization.


By Green Miles Buds Team

Thousands Of UK Patients Will Be Given Cannabis In Groundbreaking Study

The UK’s first large-scale cannabis study and biggest marijuana health investigation in European history has been announced, raising hopes that many of the country’s health professionals will finally be swayed on the efficacy of the drug for use in treating seven different health conditions.

Substance reform organization Drug Science is administering the investigation, which is called Project TWENTY21. Neuropsychopharmacologist David Nutt, previously of the University of Bristol, will be in charge of the study, which will examine cannabis’ effects on chronic pain, multiple sclerosis, epilepsy, post-traumatic stress disorder, Tourette’s syndrome, anxiety disorder, and substance abuse.

Earlier this year, media reports found that many UK hospitals were refusing to recommend medical cannabis based on “the risk of serious side effects.” Pain management clinic staff members were quoted saying, “We would welcome high-quality studies into the use of cannabis-based medicinal products for pain treatment.”

All the more reason to be excited about the Project TWENTY21 study, which will fund medical cannabis treatment for 20,000 patients by the end of 2021. The project has previously announced that it will be doing work in the fields of prison population harm reduction and the use of cannabis as a counterweight to drug addiction.


“I believe cannabis is going to be the most important innovation in medicine for the rest of my life,” commented Nutt. “There are children who have died in this country in the last couple of years because they haven’t had access to cannabis. It’s outrageous, it’s unnecessary and we want to rectify it.”

Although Health England has been extremely slow to endorse cannabis as medication, Project TWENTY21 has the co-sign of the British Pain Society, United Patients Alliance, and the Royal College of Psychiatrists.

“The College welcomes this pilot project which it hopes will make an important contribution towards addressing the paucity of evidence for the use of cannabis-based medicinal products,” commented the institution’s president Wendy Burn.

“We hope that this project, along with other research such as more much-needed [randomized] control trials, will continue to build the evidence on [cannabis-based medicinal products],” she continued.

Cannabis in the UK

It’s not the only cannabis study being conducted in the UK. University of Westminster researchers recently released the results of an investigation that concluded CBD could be a useful tool in the fight against antibiotics resistance, which currently costs the lives of some 5,000 people in England every year, according to the country’s public health agency.

Medical cannabis has been legal in the UK since October 2018. But the issue of medical marijuana has been of much debate in the country, its urgency exacerbated by the mounting problem of opioid addiction.

A prime motivator in the case of Great Britain has been the drug’s efficacy when it comes to sick kids. Young people like eight-year-old epilepsy patient Alfie Dingley and five-year-old Indie-Rose Montgomery, whose cannabis oil to treat her seizures was confiscated at London Stansted Airport in July, have shown the public how the issue is affecting fellow Brits.


By The Green Miles Buds

How To Stay Elevated In The World Of Cannabis Advertising

Close your eyes and imagine you have just been struck by an entrepreneurial lightning bolt of an idea for a new company. Your keyboard can’t keep up with your fingers as the business plan dances across your laptop’s screen. And as you begin researching the marketing strategy, the typing comes to a grinding halt. That’s because you are writing a business plan for cannabis.

The cannabis space is like the Wild West. I recently attended Hall of Flowers, a free-wheeling weed convention in Northern California that attracts everyone from OG growers to DTC venture capitalists. It’s exciting and wide open. There are booths with brands exhibiting their wares like Big Al’s Exotics, Space Coyote, Hollyweed, Legion of Bloom and my personal favorite, Terp Hogs. It’s a strange blend of a Stanford MBA mixer meets Comic-Con, where half of the attendees are stoned and the other half are euphorically buzzing from the entrepreneurial possibilities of becoming the next big bud brand. THC-infused root beer? Sure. Farm to edible vegan truffles? Great. 500-count pillowcases infused with CBD? Awesome. But a rude awakening awaits on the marketing side of the business. That’s because cannabis brands like Big Al’s Exotics can’t say the word cannabis or even show the product in most ad units.

The global legal marijuana market is rapidly growing, and is projected to break $40 billion by the end of 2024, creating a massive opportunity for entrepreneurs to profit in this rapidly evolving industry. But for advertising agencies, cannabis brands and marijuana dispensaries, marketing brings its own set of problems. FTC regulations, corporate compliance, major tech platforms and decades-old biases restrict what cannabis brands can say and where they can say it.

Let’s start with the big tech platforms. Google, YouTube, Facebook and Instragram’s guidelines all prohibit cannabis advertising. Google’s guidelines prohibit “ads for substances that alter mental state for the purpose of recreation or otherwise induce ‘highs.’” Interestingly, both Facebook and Google do not permit non-psychoactive CBD advertising as well, describing it as “an illegal pharmaceutical,” but “do allow for content to promote the use of CBD and hemp.” Confused? We are just getting started.

How about TV? Not when the FCC is involved. Network and cable stations are regulated by the FCC, which, you guessed it, is a branch of the federal government, which considers possession and distribution of cannabis a felony. The potential exception is at the ZIP code level, where inventory is so small the FCC does not regulate the category. Another potential option is digital TV on closed networks such as hotels, and certain states allow cinema spots during R-rated movies.

OK, so now we may be getting somewhere. We pair limited TV, cinema, radio, outdoor a thousand feet from schools, a cat-and-mouse game of subtle editorial Instagram posts, print and content housed on a hosted YouTube page.

Now, let’s do some killer creative in this awesome emerging space. Remember that local TV buy? The cable company is not letting you say the word cannabis or show the plant. Back in the summer of 2018, my agency Mekanism was given this very brief. MedMen, a Los Angeles-based cannabis retailer, wanted to create the world’s first cannabis TV commercial, but we could not say or show any product sold in their stores. This required some creativity.

In the two-minute film “The New Normal,” directed by Spike Jonze, we open on George Washington standing in his hemp farm, holding up a five-leaf non-psychoactive hemp plant while the voiceover cryptically says that “a president grew his own.” In the first five seconds of the ad, the creatives established a contextual cannabis reference while throwing a head fake at the FCC restrictions.

But 48 hours before it was to air, the spot was banned from appearing on television. Not because we ran afoul of any rules, but because the compliance team at the cable provider simply “felt” that the spot was problematic. No history-making prime time for MedMen. Welcome to the Wild West of cannabis advertising.

So, how do cannabis brands creatively stick it to the man when the Feds, corporate compliance and media obfuscation can harsh the green-rush mellow?

1. Avoid weed tropes in the creative.

Flagrant references to kind nugs, 420 gags and bong water only contribute to compliance’s reefer madness hysteria, so keep the creative clever, well designed and subtle.

2. Lean into earned media ideas.

Unexpected partnerships, smart editorial and celebrity endorsements will complement and elevate impressions above a foundational media plan.

3. Embrace the fundamentals.

Human insights that are informed by smart strategy and data will always spark the big idea.

As a judge for the 2019 Clio Cannabis Awards, I can see how nascent and exciting the category is. It reminds me of the golden age of digital advertising in the early 2000s, when small upstart dot-coms broke through with brilliant creative. We are in a time when nationwide federal regulation, reactionary compliance and corporate cannabis can buzzkill the creative and entrepreneurial spirit. But I’m optimistic that creativity and weed will rise above and we’ll look back at 2020 as the golden age of cannabis advertising.


As medical marijuana continues to blaze its path all throughout Canada and the rest of North America, demand for its products and accessories continue to grow. Recent waves of legalization have opened up new opportunities for patients who have long been suffering from various illnesses and disorders of all types. CBD hemp treatments have shown great promise and effectiveness in helping people with a broad range of issues.

Not only has this form of therapy become a popular agent for physical problems such as chronic pain, insomnia, and fibromyalgia, as well as the side effects from cancer treatments, it has also been effective in treating neurological conditions including Parkinson’s disease and epilepsy. And that’s not all; psychological disorders such as Anorexia, ADHD, and bulimia, have been shown to respond well to medical cannabis prescriptions, as have even some emotional conditions like depression and anxiety.

The first step to beginning this course of therapy is to apply for and receive approval for a medical marijuana prescription. The process is not a difficult one, but it needs to be done correctly all the way from filling out the paperwork accurately and sending it to the proper agencies which handle the applications, to having the medical professional’s recommendation for this type of treatment for your condition.

Obtaining a Prescription

The first thing that is needed before you have your initial consultation regarding medicinal cannabis therapy and whether or not it is the right choice for you, is a copy of your medical file and treatment history. This can be acquired by a simple request to your current personal or family physician. Often times patients may be hesitant or nervous about asking for such a document for fear of having to answer a bunch of questions or justify their request. There is no need to feel this way.


These are your records concerning your body. You have a legal right to access them at any time without providing any reason or further information regarding why you need them. The worst case scenario is that your doctor might require a written, formal request for the purposes of record keeping. Other than that, you should face no further issues. While this is not necessary if your primary physician is the one you will be consulting with regard to the possibility of medical cannabis treatments, for people seeking other opinions these files will be necessary.

Working with Specialty Clinics and Doctors

It can be advantageous to partner up with health facilities that specialize in this form of therapy as their superior knowledge in the field, and access to larger varieties of specific strains can be much more helpful when deciding which particular medication would be best for your condition(s). For medical practitioners who offer CBD products as only one of many options, their lack of expertise can often times result in an inefficient treatment program.

Filling Your Prescription

As previously mentioned, this is another advantage of working with one of the specialized health and wellness centres whose doctors and staff focus solely on medical cannabis. In addition to the fact that many of them have years of experience studying various medical conditions and how different individual strains work to treat and manage each symptom, they also have access to Licensed Providers which offer a higher quality grade of medicines than are available in retail outlets and dispensaries.

In addition to the fact that these clinics take the guesswork out of which strands to purchase for the patient, they also continue to work with them all throughout the course of the treatment, monitoring their progress and making any changes or adjustments that may be necessary, such as trying different prescriptions or adjusting the dosage based on the individual’s evolving needs.